Gastric microbiota transplantation as a potential treatment for immune checkpoint inhibitor-associated gastritis

doi:10.3748/wjg.v30.i24.3123

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 30, Issue 24

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2603)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

129

HTML

1651

Sum=1780

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

133

Download

541

Sum=674

Jun 28, 2024 (publication date) through Feb 27, 2026

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Letter to the Editor

World J Gastroenterol. Jun 28, 2024; 30(24): 3123-3125
Published online Jun 28, 2024. doi: 10.3748/wjg.v30.i24.3123

Gastric microbiota transplantation as a potential treatment for immune checkpoint inhibitor-associated gastritis

Bo-Tong Ma, Li-Xuan Sang, Bing Chang

Bo-Tong Ma, Bing Chang, Department of Gastroenterology, The First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning Province, China

Li-Xuan Sang, Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang 110022, Liaoning Province, China

Author contributions: Ma BT wrote the original draft; Sang LX and Chang B revised the manuscript; and all authors have read and approved the final version of the manuscript.

Conflict-of-interest statement: There are no conflicts of interest to report.

Corresponding author: Bing Chang, MD, PhD, Chief Physician, Professor, Department of Gastroenterology, The First Affiliated Hospital of China Medical University, No. 155 Nanjing North Street, Shenyang 110001, Liaoning Province, China. cb000216@163.com

Received: April 27, 2024
Revised: May 27, 2024
Accepted: June 13, 2024
Published online: June 28, 2024
Processing time: 58 Days and 18.1 Hours

Abstract

Immune-related adverse events (irAEs) are complications of the use of immune checkpoint inhibitors (ICIs). ICI-associated gastritis is one of the main irAEs. The gastric microbiota is often related to the occurrence and development of many gastric diseases. Gastric microbiota adjustment may be used to treat gastric disorders in the future. Faecal microbiota transplantation can alter the gut microbiota of patients and has been used for treating ICI-associated colitis. Therefore, we propose gastric microbiota transplantation as a supplementary treatment for patients with ICI-associated gastritis who do not respond well to conventional therapy.

Keywords: Immune checkpoint inhibitor; Immune-related adverse events; Gastritis; Gastric microbiota transplantation; Probiotics

Core Tip: The gastric microbiota is often related to the occurrence and development of many gastric diseases. Faecal microbiota transplantation has been used for treating immune checkpoint inhibitor (ICI)-associated colitis. Therefore, gastric microbiota transplantation is a promising treatment for ICI-associated gastritis.